Swiss biotech Memo Therapeutics lands €13.9 million to advance its COVID-19 antibody treatment
Summary
“We are thrilled that with Swisscanto Invest and Bernina BioInvest we could attract two new renowned investors into our existing syndicate to support the clinical development of our two antiviral assets. We see this as validation of our antibody discovery approach and the huge future potential for the company,” said Dr. Karsten Fischer, CEO of Memo Therapeutics AG. Dr. Christoph Esslinger, CSO and co-founder of Memo Therapeutics AG added: “Our concept to discover antibodies from convalescent human donors within 3 weeks and to develop that idea within 9 months to first-in-human has been a huge effort by the entire team. MTX-COVAB is a fully human, highly potent antibody isolated from clinically selected convalescent COVID-19 donors that also neutralizes all major known mutants. We are excited to be providing financial support, which will enable the Memo Therapeutics AG team to move further into clinical proof of concept.